References
- Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, et al. International trends in antipsychotic use: A study in 16 countries, 2005–2014. Eur Neuropsychopharmacol. 2017; 27(10): 1064–76.
- Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002; 24(4): 518–26.
- Batail JM, Langrée B, Robert G, Bleher S, Verdier MC, Bellissant E, et al. Use of very-high-dose olanzapine in treatment-resistant schizophrenia. Schizophr Res. 2014; 159(2–3): 411–4.
- Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm. 2007; 64(18): 1917–21.
- Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol. 2006; 58(7): 871–85.
- Sachse C, Brockmöller J, Bauer S, Roots I. Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999; 47(4): 445–9.
- Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol. 2007; 63(6): 537–46.
- Patel MX, Bowskill S, Couchman L, Lay V, Taylor D, Spencer EP, et al. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999–2009. J Clin Psychopharmacol. 2011; 31(4): 411–7.
- Söderberg MM, Haslemo T, Molden E, Dahl ML. Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. Pharmacogenomics J. 2013; 13(6): 544–50.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Washington, DC, American Psychiatric Association, 2013.
- Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines in Psychiatry, 12th Edition. London, Wiley-Blackwell, April 2015, pp. 90–143.
- World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20): 2191–4.
- Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962; 10: 799–812.
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–76.
- Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005; 162(3): 441–9.
- Ehmer U, Vogel A, Schütte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology. 2004; 39(4): 970–7.
- Saeki M, Saito Y, Jinno H, Sai K, Hachisuka A, Kaniwa N, et al. Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet. 2005; 20(2): 144–51.
- López M, Dorado P, Ortega A, Peñas-Lledó E, Monroy N, Silva-Zolezzi I, et al. Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations. Mol Biol Rep. 2013; 40(4): 3187–92.
- International HapMap Project. Available online:
https://catalog.coriell.org/1/NHGRI/Collections/HapMapCollections/HapMap-Project (accessed on 1 April 2024). - Arici M, Özhan G. The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population Saudi Pharm J. 2017; 25(2): 294–7.
- Salinero JJ, Lara B, Ruiz-Vicente D, Areces F, Puente-Torres C, Gallo-Salazar C, et al. CYP1A2 Genotype Variations Do Not Modify the Benefits and Drawbacks of Caffeine during Exercise: A Pilot Study. Nutrients. 2017; 9(3): 269.
- Urry E, Jetter A, Landolt HP. Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake. Nutr Metab (Lond). 2016; 13: 66.
- Sulem P, Gudbjartsson DF, Geller F, Prokopenko I, Feenstra B, Aben KK, et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Mol Genet. 2011; 20(10): 2071–7.
- Barbieri RB, Bufalo NE, Cunha LL, Assumpção LV, Maciel RM, Cerutti JM, et al. Genes of detoxification are important modulators of hereditary medullary thyroid carcinoma risk. Clin Endocrinol (Oxf). 2013; 79(2): 288–93.
- Bushueva O, Solodilova M, Churnosov M, Ivanov V, Polonikov A. The Flavin-Containing Monooxygenase 3 Gene and Essential Hypertension: The Joint Effect of Polymorphism E158K and Cigarette Smoking on Disease Susceptibility. Int J Hypertens. 2014; 2014: 712169.
- Tang Y, Hu K, Huang W, Wang C, Liu Z, Chen Y, et al. Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers. Biomed Res Int. 2017; 2017: 4189678.
- Dolan C, Shields DC, Stanton A, O'Brien E, Lambert DM, O'Brien JK, et al. Polymorphisms of the Flavin containing monooxygenase 3 (FMO3) gene do not predispose to essential hypertension in Caucasians. BMC Med Genet. 2005; 6: 41.
- Park CS, Kang JH, Chung WG, Yi HG, Pie JE, Park DK, et al. Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities. Pharmacogenetics. 2002; 12(1): 77–80.
- Rajman I, Knapp L, Morgan T, Masimirembwa C. African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development. EBioMedicine. 2017; 17: 67–74.
- Dean L. Tamoxifen therapy and CYP2D6 genotype. In: Medical Genetics Summaries. National Center for Biotechnology Information (US): Bethesda; 2016.
- LLerena A, Naranjo ME, Rodrigues-Soares F, Penas-LLedó EM, Fariñas H, Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol. 2014; 10(11): 1569–83.
- Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, et al. Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations. Pharmgenomics Pers Med. 2017; 10: 93–9.
- De Ameida Melo M, De Vasconcelos-Valença R, Neto F, Borges R, Costa-Silva D, Da Conceição Barros-Oliveira M, et al. CYP2D6 gene polymorphisms in Brazilian patients with breast cancer treated with adjuvant tamoxifen and its association with disease recurrence. Biomed Rep. 2016; 5(5): 574–8.
- Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M, et al. UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems. Clin Pharmacol Ther. 2012; 92(2): 221–7.
- Czerwensky F, Leucht S, Steimer W. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. Ther Drug Monit. 2015; 37(2): 152–60.
- Erickson-Ridout KK, Zhu J, Lazarus P. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet Genomics. 2011; 21(9): 539–51.